Engineered Natural Killer Cell Derived-Extracellular Vesicles: An Acellular Immunotherapy with Cytotoxic Effects in SNU-1079 Human Cholangiocarcinoma Cells
Open Access
- 17 August 2026
- journal article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (9) , 4540-4552
Abstract
The use of natural killer (NK) cells for the treatment of solid tumors such as cholangiocarcinoma has been hindered by challenges related to cell production, persistence and trafficking, as well as by reduced efficacy within an immunosuppressive tumor microenvironment. Antitumor immunity can be reduced by the interaction of NK cell expressed programmed cell death protein 1 (PD1) with ligands on tumor and other cells within the tumor microenvironment. The antitumor effect of NK cells is enhanced in cells engineered to express a truncated PD1 without an intracellular domain. The cytolytic potential and therapeutic efficacy of extracellular vesicles (EVs) derived from human NK cells expressing truncated PD1 was evaluated as a cell-free therapeutic to overcome some limitations faced by cell therapies. We demonstrate the feasibility of efficient expansion, production and isolation of therapeutic vesicles from human NK cell lines and from engineered NK92 cells expressing truncated PD1. The cytotoxic efficacy of these therapeutic vesicles was validated in both monolayer tumor cell cultures and in multicellular tumor spheroids. Concomitant administration of gemcitabine upregulated NKG2D ligands on tumor cells and increased susceptibility to NK cell and to NK cell derived EV mediated killing. These findings position engineered NK cell derived-EVs as a scalable and promising cell-free immunotherapeutic for cholangiocarcinoma.Keywords
Funding Information
- Graduate Program in Physics at UNIFAL-MG (NA)
- Graduate Program in Physics at UNIFAL-MG (NA)
This publication has 37 references indexed in Scilit:
- Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor ImmunityAdvanced Science, 2026
- Surface‐Engineered Natural Killer Cell‐Derived Small Extracellular Vesicles Induce Potent Anti‐Tumour Effects in Lung Cancer CellsJournal of Extracellular Biology, 2025
- NK-derived exosomes in anti-tumor strategiesMedical Oncology, 2025
- Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcomeCancer Immunology, Immunotherapy, 2023
- Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic CholangiocarcinomaHepatology, 2019
- Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 primingBiomaterials, 2019
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK CellsCell, 2018
- Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinomaHepatology, 2013
- Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patientsClinical Immunology, 2008
- Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphismsHepatology, 2007